Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users
Tóm tắt
The objective of the study was to determine whether measures taken to prevent human immunodeficiency virus (HIV) infection also lead to a reduction in the prevalence of hepatitis C virus (HCV) infection among intravenous drug users (IDU). Antibodies to HCV, HIV and hepatitis B virus (HBV) were determined in IDU who voluntarily attended AIDS prevention and information centres for the first time between 1990 and 1996. Of the 5473 IDU studied, determination of HCV was done in 3238 cases. The prevalence of antibodies to HCV was 85%. During the first period studied (1990–1992), the prevalence of antibodies to HCV was 84.5%, during the second (1993–1994) 84.1% and during the third (1995–1996) 87%; in the case of HBV the prevalence during the three periods was 74.5, 67.6 and 66.8% respectively, and for HIV it was 41.9, 38.8 and 36.6% respectively (RR: 0.72; 95% confidence interval (CI): 0.65–0.81). Among drug users addicted for less than 2 years, the trend of the prevalence of antibodies to HCV and HBV remained constant, while the prevalence of HIV infection decreased (RR: 0.61; 95% CI: 0.42–0.89). Measures to prevent transmission of HIV in drug users do not lead to a reduction in the prevalence of HCV infection. Further study is necessary to obtain a better understanding of how HCV is transmitted among drug users in order to apply measures which are effective in preventing HCV infection.
Tài liệu tham khảo
Patti AM, Santi AL, Pompa MG, et al. Viral hepatitis and drugs: A continuing problem. Int J Epidemiol 1993; 22: 135–139.
Thomas DL, Vlahov D, Salomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212–220.
Bolumar F, Hernández-Aguado I, Ferrer L, Ruiz I, Aviñó J, Rebagliato M. Prevalence of antibodies to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990–1992. Int J Epidemiol 1996; 25: 204–209.
Van-Ameijdenn EJ, Van den Hoek JA, Nientjes GH, Coutunho RA. A longitudinal study on the incidence and transmission of HIV, HBV, and HCV infection and drug users in Amsterdam. Eur J Epidemiol 1993; 9: 255–262.
Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U. Prevalence and determinants of anti-HCV seropositivity and HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 1995; 27: 331–337.
Francisci D, Baldelli F, Papolo R, Stagni G, Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995; 11: 123–126.
Donahue JG, Nelson KE, Muñoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991; 134: 1.206–1.211.
Quan CM, Krajden M, Grigriew GA, Salit IE. Hepatitis C virus infection in patients with the human immunodeficiency virus. Clin Infect Dis 1993; 17: 117–119.
Van Beek I, Buckley R, Stewrt M, MacDonald M, Kaldor J. Risk Factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70: 321–324.
Chetwynd J, Brunton C, Blank M, Plumridge E, Baldwin D. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programs. N Z Med J 195;108: 364–366.
Delgado-Iribarren A, Wihwelmi I, Padilla B, Cañedo T, Gómez J, Elviro J. Infección por VIH y por los virus de la hepatitis B, C, y D en adictos a dragos por vá parenteral. Seroprevalencia de un año y su seguimiento. Enferm Infecc Microbiol Clin 1993; 11: 8–13.
Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in United States. N Egl J Med 1992; 327: 1.899–1.905.
Salleras L, Bruguera M, Vidal J, et al. Importance of sexual transmission of hepatitis C virus in seropositive pregnant women: A case–control study. J Med Virol 1997; 52: 164–167.
Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 765–768.
Nakashima K, Kashiwaagi S, Hayashi J, et al. Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted disease in Fukuoka, Kysshu, Japan. Am J Epidemiol 1992; 136: 1.132–1.137.
Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore – an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768–775.
Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993; 12: 827–831.
Battjes RJ, Pickens RW, Brown S. HIV infection and AID risk behaviors among injecting drug users entering methadone treatment: An update. J Acquir Immune Defic Syndr 1995; 10: 90–96.
Hernández-Aguado I, Aviñó MJ, Perez-Hoyos S, et al. HIV infection in parenteral drug users: evolution of the epidemic over 10 years. Int J Epidemiol 1999; 28: 335–340.
Camps Bansell J, Esteban Mur R. Hepatitic C. Enferm Infecc Microbiol Clin 1995; 13(Suppl. 1): 31–39.
Hernandez Aguado I, Ruiz I, Bolumar F, et al. Sharing of injection equipment among 3755 intravenous drug users in Valencia, Spain, 1987–1992. Int J Epidemiol 1994; 23: 602–607.
Stark K, Bienzle U, Vonk R, Guggenmoods-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997; 26: 1359–1365.
Grund J-PC, Kaplan CD, Adriaans NFP, Blanken P, Huisman J. The limitations of the concept of needle sharing: The practice of frontloading. AIDS 1990; 4: 819–821.
MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: Rates, routes and cofactors. Epidemiol Rev 1996; 18: 137–148.
Stark K, Müller R, Bienzle U, Guggenmoos-Holzmann I. Frontloading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 1996; 10: 311–317.
Ross RS, Viazov S, Gross T, Hofmann F, Seipp H-M, Roggendorf M. Brief Report: Transmission of Hepatitis C Virus from a Patient to an Anesthesiology Assistant to Five Patients. N Engl J Med 2000; 343: 1851–1854.
Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent hepatitis C: Di.erences among adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 91: 23–30.
Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42–46.
Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunode.ciency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690–695.
Soriano V, García-Samaniego J, Bravo R, et al. Morbilidad y mortalidad asociadas a hepatopatía crónica viral en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1995; 104: 641–644.
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–733.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–739.